---
title: "DINGHAN TECH establishes a new subsidiary that includes integrated circuit design business"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240511494.md"
description: "According to the Qichacha APP, recently, Dalian DINGHAN TECH Co., Ltd. was established, with Wan Qing as the legal representative. The business scope includes: manufacturing of railway transportation infrastructure equipment; manufacturing of railway locomotives and vehicles; manufacturing of internet equipment; integrated circuit design, etc. Qichacha's equity penetration shows that the company is wholly owned by DINGHAN TECH"
datetime: "2025-05-16T06:43:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240511494.md)
  - [en](https://longbridge.com/en/news/240511494.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240511494.md)
---

# DINGHAN TECH establishes a new subsidiary that includes integrated circuit design business

According to the Qichacha APP, recently, Dalian DINGHAN TECH Co., Ltd. was established, with Wan Qing as the legal representative. The business scope includes: manufacturing of railway transportation infrastructure equipment; manufacturing of railway locomotives and vehicles; manufacturing of internet equipment; integrated circuit design, etc. Qichacha's equity penetration shows that the company is wholly owned by DINGHAN TECH

### Related Stocks

- [300011.CN](https://longbridge.com/en/quote/300011.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Phenom Hires Project Manager for its Gold Exploration in Nevada | PHNMF Stock News](https://longbridge.com/en/news/287071365.md)
- [Key facts: Tata Steel strong Q4; Netherlands unit EBITDA-positive](https://longbridge.com/en/news/286842740.md)
- [15:37 ETMuse Communications Celebrates 10 Years of Award-Winning Legal Marketing and Public Relations](https://longbridge.com/en/news/286811115.md)
- [20:00 ETAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases](https://longbridge.com/en/news/286830151.md)